芬那酯作为经典的非甾体抗炎药广泛用于缓解疼痛。临床前研究和流行病学数据强调了它们对癌症的化学预防和化疗潜力。然而，对芬那酯在癌症中的综合评价是有限的。为了加速芬那酯的重新利用，本综述总结了芬那酯单独使用或与现有化疗药物联合使用的结果。本文还探讨了芬那酯在癌症治疗中的靶点，包括COX、AKR家族、AR、间隙连接、FTO、TEAD、DHODH、TAS2R14、离子通道和DNA。此外，本文还讨论了其他机制，如调节Wnt/β-catenin、TGF-β、p38 MAPK和NF-κB通路，以及Sp、EGR-1、NAG-1、ATF-3表达的调节、ErbB2、AR，以及肿瘤免疫微环境的调节。此外，本文概述了芬那酯的结构修饰，强调了它们作为抗癌药物的潜在先导化合物的潜力。© 2024 Wiley periodicals LLC。

Fenamates as classical nonsteroidal anti-inflammatory agents are widely used for relieving pain. Preclinical studies and epidemiological data highlight their chemo-preventive and chemotherapeutic potential for cancer. However, comprehensive reviews of fenamates in cancer are limited. To accelerate the repurposing of fenamates, this review summarizes the results of fenamates alone or in combination with existing chemotherapeutic agents. This paper also explores targets of fenamates in cancer therapy, including COX, AKR family, AR, gap junction, FTO, TEAD, DHODH, TAS2R14, ion channels, and DNA. Besides, this paper discusses other mechanisms, such as regulating Wnt/β-catenin, TGF-β, p38 MAPK, and NF-κB pathway, and the regulation of the expressions of Sp, EGR-1, NAG-1, ATF-3, ErbB2, AR, as well as the modulation of the tumor immune microenvironment. Furthermore, this paper outlined the structural modifications of fenamates, highlighting their potential as promising leads for anticancer drugs.© 2024 Wiley Periodicals LLC.